Panjideh H - Search Results

1

Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.

Fuchs H, Niesler N, Trautner A, Sama S, Jerz G, Panjideh H, Weng A. Fuchs H, et al. Among authors: panjideh h. Biomedicines. 2017 Mar 29;5(2):14. doi: 10.3390/biomedicines5020014. Biomedicines. 2017. PMID: 28536357 Free PMC article. Review.

2

A33scFv-green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting.

Petrausch U, Dernedde J, Coelho V, Panjideh H, Frey D, Fuchs H, Thiel E, Deckert PM. Petrausch U, et al. Among authors: panjideh h. Protein Eng Des Sel. 2007 Dec;20(12):583-90. doi: 10.1093/protein/gzm043. Epub 2007 Nov 22. Protein Eng Des Sel. 2007. PMID: 18033820

3

Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants.

Panjideh H, Coelho V, Dernedde J, Fuchs H, Keilholz U, Thiel E, Deckert PM. Panjideh H, et al. Bioprocess Biosyst Eng. 2008 Oct;31(6):559-68. doi: 10.1007/s00449-008-0203-y. Epub 2008 Feb 6. Bioprocess Biosyst Eng. 2008. PMID: 18253756

4

Saponins as tool for improved targeted tumor therapies.

Fuchs H, Bachran D, Panjideh H, Schellmann N, Weng A, Melzig MF, Sutherland M, Bachran C. Fuchs H, et al. Among authors: panjideh h. Curr Drug Targets. 2009 Feb;10(2):140-51. doi: 10.2174/138945009787354584. Curr Drug Targets. 2009. PMID: 19199910 Review.

5

Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase.

Schellmann N, Panjideh H, Fasold P, Bachran D, Bachran C, Deckert PM, Fuchs H. Schellmann N, et al. Among authors: panjideh h. J Immunother. 2012 Sep;35(7):570-8. doi: 10.1097/CJI.0b013e31826b1fb4. J Immunother. 2012. PMID: 22892453

6

Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.

Panjideh H, Niesler N, Weng A, Fuchs H. Panjideh H, et al. Toxins (Basel). 2022 Jul 13;14(7):478. doi: 10.3390/toxins14070478. Toxins (Basel). 2022. PMID: 35878216 Free PMC article.

7

Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478.

Panjideh H, Niesler N, Weng A, Fuchs H. Panjideh H, et al. Toxins (Basel). 2022 Oct 13;14(10):703. doi: 10.3390/toxins14100703. Toxins (Basel). 2022. PMID: 36287991 Free PMC article.

8

Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.

Coelho V, Dernedde J, Petrausch U, Panjideh H, Fuchs H, Menzel C, Dübel S, Keilholz U, Thiel E, Deckert PM. Coelho V, et al. Among authors: panjideh h. Int J Oncol. 2007 Oct;31(4):951-7. Int J Oncol. 2007. PMID: 17786329

9

Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.

Panjideh H, Da Silva Coelho VC, Dernedde J, Bachran C, Förster GJ, Franke J, Fasold P, Fuchs H, Thiel E, Deckert PM. Panjideh H, et al. Int J Oncol. 2008 Apr;32(4):925-30. Int J Oncol. 2008. PMID: 18360720

10

Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.

Panjideh H, Müller G, Koch M, Wilde F, Scheu S, Moldenhauer G, Lipp M. Panjideh H, et al. Int J Cancer. 2014 Dec 1;135(11):2623-32. doi: 10.1002/ijc.28893. Epub 2014 Apr 29. Int J Cancer. 2014. PMID: 24729415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters